Tridek-One, a biotechnology start-up specializing in the research and development of CD31 agonists to restore immune balance, has just announced a fundraising of 16 million euros during a funding round led by the Swiss Pureos BioVentures. This operation is being carried out alongside newcomers Bpifrance, through its InnoBio2 fund, and Bioqube Ventures (Belgium), with the participation of historical investors AdBio partners and Advent Life Sciences. The funds will first be used to identify drug candidates to be developed against autoimmune diseases, to conduct regulatory preclinical studies and to structure the company. In 2019, Tridek-One had raised 3 million euros during a first funding round with AdBio partners (France) and Advent Life Sciences (United Kingdom).
Founded in 2018 by Dr Giuseppina Caligiuri and Pr Antonino Nicoletti, researchers in INSERM unit 1148 (Paris), with the support of AdBio partners as historical investor, Tridek-One is developing a CD31 agonist approach intended to modulate immune activation for the treatment of autoimmune diseases.
Tridek-One has also appointed Laurence de Schoulepnikoff as CEO, effective July 1, 2022. An expert in the pharmaceutical and biotech industry, Laurence de Schoulepnikoff has extensive experience in transactions and R&D activities in the field. life sciences. She has worked for biotech start-ups funded by venture capital firms and for mid-sized private companies, as well as multinationals. Prior to joining Tridek-One, she was Director of Business Development and Director of Operations at AMAL Therapeutics, a Swiss biotechnology company specializing in therapeutic oncology vaccines. AMAL was acquired in 2019 by Boehringer Ingelheim. At Tridek-One, Ms. de Schoulepnikoff will be in charge of strategy and development, as well as the consolidation of the company’s structure.
“I am delighted to join Tridek-One and grateful for this opportunity to lead the company as we enter a strategic period where we expect to reach several major preclinical milestones and build a leading biotech for the treatment of autoimmune diseases,” says Laurence de Schoulepnikoff, CEO of Tridek-One.
Following this funding round, Klaus Breiner from Pureos Bioventures and Benoit Barteau from Bpifrance join the company’s board of directors, as does Erik van den Berg, CEO of AM-Pharma, who becomes its independent chairman.
“I am delighted to join Tridek-One as Chairman, as the company grows stronger with an experienced team and with the support of a syndicate of international investors who have chosen to trust decades of research conducted by the team of Dr Giuseppina Caligiuri and Pr Antonino Nicoletti”, adds Erik van den Berg.
“There is still a significant unmet medical need in many autoimmune diseases. The agonist approach of inhibitory receptors of the immune system, such as CD31, could rebalance the immune system without a systemic immunosuppressive effect. We are delighted to develop this concept with Tridek-One and to support them in their research and preclinical stages,” explains Klaus Breiner, Associate Director at Pureos Bioventures.
“AdBio partners was a founding investor of Tridek-One in 2018, we were then joined by Advent Life Sciences. We are delighted to welcome new investors who strongly believe in Tridek-One’s disruptive innovation. This confirms our initial choice as an entrepreneur-investor”, declares Alain Huriez, president of AdBio partners.
“Being supported by investors who believe in the Tridek-One project is a fantastic opportunity. This will allow us to accelerate our work to identify and develop first-in-class immune checkpoint agonists capable of controlling serious inflammatory diseases”, conclude Dr. Giuseppina Caligiuri and Prof. Antonino Nicoletti, Scientific Founders from Tridek-One.
Source and visual: Tridek-On
Share the post “Tridek-One raises 16 million euros to develop first-in-class anti-checkpoint immunotherapies”